{
    "clinical_study": {
        "@rank": "137826", 
        "arm_group": [
            {
                "arm_group_label": "AMG 876", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and\n      pharmacodynamics following ascending multiple doses of AMG 876 in subjects with type 2\n      diabetes."
        }, 
        "brief_title": "Multiple Ascending Dose Study in Subjects With Type 2 Diabetes", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female subjects \u2265 18 to \u2264 65  years of age at the time of randomization\n\n          -  Female subjects must be of documented non-reproductive potential\n\n          -  Diagnosed with type 2 diabetes\n\n          -  HbA1c \u2265 6.5% and \u2264 10%\n\n          -  Fasting C-peptide value \u2265 0.8 ng/mL\n\n          -  Body mass index (BMI) between \u2265 25.0 and \u2264 40.0 kg/m2 at screening\n\n        Exclusion Criteria:\n\n          -  Female subjects who are lactating/breastfeeding or who plan to breastfeed while on\n             study through 4 weeks after receiving the last dose of study drug.\n\n          -  Male subjects with partners who are pregnant or planning to become pregnant while the\n             subject is on study through 4 weeks after receiving the last dose of study drug\n\n          -  Evidence or history at screening of diabetic complications with significant end-organ\n             damage, eg, proliferative retinopathy and/or macular edema, estimated glomerular\n             filtration rate < 60 mL/min/1.73m2 (calculated using the Modification of Diet in\n             Renal Disease formula) or macroalbuminuria (ie, \u2265 +1 proteinuria on urinalysis),\n             diabetic neuropathy complicated by neuropathic ulcers, or severe autonomic neuropathy\n             with gastroparesis, chronic diarrhea, or hypoglycemic unawareness\n\n          -  Significant cardiac disease, including but not limited to, evidence or history of\n             coronary artery disease, unstable angina, congestive heart failure, known arrhythmias\n             of atrial or ventricular etiology, unexplained syncope, or syncope/seizures related\n             to arrhythmia\n\n          -  Uncontrolled hypertension (systolic blood pressure \u2265 150 mmHg or diastolic blood\n             pressure \u2265 90 mmHg) either on or off therapy at screening\n\n          -  Triglycerides \u2265 500 mg/dL (5.64 mmol/L) at screening\n\n          -  Hepatic liver enzymes ALT, AST, alkaline phosphatase (ALP), or total bilirubin (TBIL)\n             levels > 1.5 times the upper limit of normal (ULN) at screening\n\n          -  Fasting blood glucose > 270 mg/dL at the screening visit\n\n          -  Positive for human immunodeficiency virus (HIV) antibodies, hepatitis B surface\n             antigen (HbsAg), or hepatitis C virus antibodies (HepCAb)\n\n          -  An unstable medical condition, defined as having been hospitalized within 28 days\n             before day -1, major surgery within 6 months before day -1, or otherwise unstable in\n             the judgment of the investigator (eg, risk of complications or adverse events\n             unrelated to study participation)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "124", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01856881", 
            "org_study_id": "20100018"
        }, 
        "intervention": {
            "arm_group_label": [
                "AMG 876", 
                "Placebo"
            ], 
            "description": "Ascending multiple doses of study drug administered SC", 
            "intervention_name": "AMG 876", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Type 2 diabetes", 
        "lastchanged_date": "March 19, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chula Vista", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91911"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miramar", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33025"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Overland Park", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66212"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45255"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78209"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Renton", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98057"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 876 in Subjects With Type 2 Diabetes", 
        "overall_contact": {
            "last_name": "Amgen Call Center", 
            "phone": "866-572-6436"
        }, 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Physical examinations, vitals, laboratory analytes, and ECGs", 
                "measure": "Subject incidence of treatment-emergent adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "43 Days (Cohorts 1, 3, 5 and 7), 57 Days (Cohorts 2, 4, 6 and 9) or 71 Days (Cohort 8)."
            }, 
            {
                "description": "Laboratory analytes", 
                "measure": "Subject incidence of anti-AMG 876 antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "43 Days (Cohorts 1, 3, 5 and 7), 57 Days (Cohorts 2, 4, 6 and 9) or 71 Days (Cohort 8)."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01856881"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Concentration-time profiles for AMG 876", 
                "measure": "AMG 876 serum PK parameters", 
                "safety_issue": "No", 
                "time_frame": "43 Days (Cohorts 1, 3, 5 and 7), 57 Days (Cohorts 2, 4, 6 and 9) or 71 Days (Cohort 8)."
            }, 
            {
                "description": "Concentration of fasting glucose, insulin, and C-peptide levels; Concentration-time profiles and AUC for metabolic parameters (eg, glucose, insulin, C peptide, glucagon, and non-esterified fatty acid concentrations); Fasting lipid levels (total cholesterol, low-density lipoprotein [LDL], high-density lipoprotein [HDL], and triglycerides); The following 7-point SMBG parameters: pre-meal average blood glucose, post-meal average blood glucose, 7-point average blood glucose, post-meal excursion, post-meal excursion average; Body weight, 24 hour weighted mean glucose(cohort 9 only)", 
                "measure": "Pharmacodynamic parameters", 
                "safety_issue": "No", 
                "time_frame": "43 Days (Cohorts 1, 3, 5 and 7), 57 Days (Cohorts 2, 4, 6 and 9) or 71 Days (Cohort 8)."
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}